BR112013011715A2 - formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil - Google Patents

formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil

Info

Publication number
BR112013011715A2
BR112013011715A2 BR112013011715A BR112013011715A BR112013011715A2 BR 112013011715 A2 BR112013011715 A2 BR 112013011715A2 BR 112013011715 A BR112013011715 A BR 112013011715A BR 112013011715 A BR112013011715 A BR 112013011715A BR 112013011715 A2 BR112013011715 A2 BR 112013011715A2
Authority
BR
Brazil
Prior art keywords
alkoxyimidazol
biphenyl
carboxylic acid
crystalline forms
methyl carboxylic
Prior art date
Application number
BR112013011715A
Other languages
English (en)
Inventor
Ross Fatheree Paul
Thalladi Venkat
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BR112013011715A2 publication Critical patent/BR112013011715A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013011715A 2010-11-10 2011-11-09 formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil BR112013011715A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Publications (1)

Publication Number Publication Date
BR112013011715A2 true BR112013011715A2 (pt) 2017-10-31

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011715A BR112013011715A2 (pt) 2010-11-10 2011-11-09 formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil

Country Status (19)

Country Link
US (3) US8362060B2 (pt)
EP (1) EP2638017B1 (pt)
JP (2) JP2013542258A (pt)
KR (1) KR20130130730A (pt)
CN (1) CN103189362B (pt)
AR (1) AR083828A1 (pt)
AU (1) AU2011326622B2 (pt)
BR (1) BR112013011715A2 (pt)
CA (1) CA2812598A1 (pt)
CO (1) CO6741224A2 (pt)
ES (1) ES2567721T3 (pt)
HK (1) HK1187919A1 (pt)
IL (1) IL225303A0 (pt)
MX (1) MX2013005165A (pt)
NZ (1) NZ609804A (pt)
RU (1) RU2013126403A (pt)
SG (1) SG189448A1 (pt)
TW (1) TW201300366A (pt)
WO (1) WO2012064807A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) * 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) * 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
HK1187919A1 (zh) 2014-04-17
CA2812598A1 (en) 2012-05-18
CN103189362B (zh) 2015-03-11
US8362060B2 (en) 2013-01-29
US20150133518A1 (en) 2015-05-14
US20120115920A1 (en) 2012-05-10
EP2638017B1 (en) 2016-01-27
CO6741224A2 (es) 2013-08-30
NZ609804A (en) 2015-02-27
US20130267573A1 (en) 2013-10-10
JP2013542258A (ja) 2013-11-21
KR20130130730A (ko) 2013-12-02
AR083828A1 (es) 2013-03-27
WO2012064807A1 (en) 2012-05-18
JP2016028061A (ja) 2016-02-25
US9249105B2 (en) 2016-02-02
TW201300366A (zh) 2013-01-01
US8802709B2 (en) 2014-08-12
IL225303A0 (en) 2013-06-27
MX2013005165A (es) 2013-07-05
ES2567721T3 (es) 2016-04-26
AU2011326622B2 (en) 2014-12-18
AU2011326622A1 (en) 2013-04-04
EP2638017A1 (en) 2013-09-18
CN103189362A (zh) 2013-07-03
RU2013126403A (ru) 2014-12-20
SG189448A1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
BRPI1013937A2 (pt) compostos de ácido carboxílico
BR112014029261A2 (pt) compostos de ácido carboxílico
DK2935563T3 (da) Biologisk fremgangsmåde til fremstilling af en dicarboxylfedtsyre
BR112013013247A2 (pt) troca de parâmetros relativos a períodos de medição
EP2740721A4 (en) NEW BENZOIC ACID AMID CONNECTION
ZA201306560B (en) Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
DE112012001776A5 (de) Drehmomentwandler
DK3299356T3 (da) Fremgangsmåde til fremstilling af pleuromutiliner
ZA201401901B (en) Guanidinobenzoic acid compound
BR112012000890A2 (pt) formas de base livre cristalina de um composto bifenil
LTPA2020526I1 (lt) 2-Acilaminotiazolo junginio kristalai
CL2014000290A1 (es) Uso y composicion agroquimica de dibutilamidas de acido carboxilico
BRPI1013620A2 (pt) método para produzir um composto de ácido cetomalônico
SMT201400109B (it) Composto cicloesanico
BR112013002589A2 (pt) valsatana altamente cristalina
DK2438012T3 (da) Fremgangsmåde til fremstilling af en sammensætning omfattende meso-vinsyre
BR112013011715A2 (pt) formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil
BR112013015002A2 (pt) método para obter um composto
BR112012029402A2 (pt) processos para a produção de pirrolidonas
BR112012029415A2 (pt) processos para a produção de pirrolidonas
BR112013015003A2 (pt) método para obter um composto
DK2848612T3 (da) Fremgangsmåde til fremstilling af en substitueret benzoesyreforbindelse
FI20100072A0 (fi) Uudenlainen formulaatio
BR112014000224A2 (pt) preparação de compostos nitrílicos
UA23289S (uk) Комплект етикеток

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/412,011, REIVINDICADA NO PCT/US2011/059895, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("THERAVANCE, INC") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E, MESMO APOS A ELABORACAO DE EXIGENCIA PARA TAL, NAO FOI REGULARIZADO O DOCUMENTO COMPROBATORIO DE CESSAO DA CITADA PRIORIDADE REIVINDICADA ACOMPANHADO DE SUA RESPECTIVA TRADUCAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E N

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: THERAVANCE, INC (US)